2020, Number 1
<< Back Next >>
Rev Nefrol Dial Traspl 2020; 40 (1)
Eventos clínicos graves en el tratamiento de la enfermedad de fabry
Ballena-Custodio C, Severino-Fuentes E
Language: Spanish
References: 5
Page: 90-91
PDF size: 88.94 Kb.
Text Extraction
No abstract.
REFERENCES
Jaurretche SP. Enfermedad vascular en pacientes varonescon enfermedad de Fabry en hemodiálisis: estudio decohorte retrospectivo en Argentina. Rev Nefrol DialTraspl. 2019;39(2):101-7.
Hopkin RJ, Cabrera G, Charrow J, Lemay R, MartinsAM, Mauer M, et al. Risk factors for severe clinicalevents in male and female patients with Fabry diseasetreated with agalsidase beta enzyme replacementtherapy: Data from the Fabry Registry. Mol GenetMetab. 2016;119(1-2):151-9.
Álvarez de Mon Soto M, Navas Serrano VM, PlazaRomero S (coord.). Enfermedades lisosomales. Madrid:Springer Healthcare Ibérica, 2017. 512 p.
Ortiz A, Abiose A, Bichet DG, Cabrera G, CharrowJ, Germain DP, et al. Time to treatment benefit foradult patients with Fabry disease receiving agalsidaseβ: data from the Fabry Registry. J Med Genet. 2016Jul;53(7):495-502.
Ortiz A, Sanchez-Niñoa MD. Diagnóstico ytratamiento de la enfermedad de Fabry. Med Clin(Barc.). 2017;148(3):132-8.
Full text